How Roche’s Valuation Compares to Its Peers



Roche’s valuation

As we discussed earlier in this series, Roche (RHHBY) is a multinational pharmaceutical company focused on its Pharmaceuticals and Diagnostics businesses. From an investor’s point of view, forward PE[1. price-to-earnings] and EV-to-EBITDA[2. enterprise value to earnings before interest, tax, depreciation, and amortization] multiples are the two best valuation multiples to use when valuing Roche and other large pharmaceutical companies, given the relatively stable and visible nature of their earnings.

Article continues below advertisement

Forward PE

On September 15, 2016, Roche traded at a forward PE multiple of 15.4x, which is much lower than the industry average of 18.1x.

Among its competitors, Bristol-Myers Squibb (BMY), Merck (MRK), and AstraZeneca (AZN) are trading at forward PE multiples of 19.3x, 16.2x, and 16.3x respectively.


On a capital structure–neutral basis, Roche currently trades at ~10.4x, which is much lower than the industry’s average of ~12.3x.

Among its competitors, Eli Lilly (LLY), Novartis (NVS) and GlaxoSmithKline (GSK) are trading at forward EV-to-EBITDA multiples of 14.3x, 10.3x, and 15.7x, respectively.

Analyst recommendations

According to data generated on September 15, 2016, Roche’s stock has fallen ~6% over the last 12 months. Analysts estimate that the stock has the potential to return ~15% over the next 12 months.

Analysts’ recommendations show a 12-month targeted price of $35.10 per share compared to the last price of $30.52 per share posted on September 14, 2016. According to Bloomberg’s consensus, ~75% of the analysts recommend a “buy” for Roche (RHHBY), and 25% of the analysts recommend a “hold.” Changes in analysts’ estimates and recommendations are based on changing trends in the stock’s price.

Investors can consider the Vanguard FTSE Europe ETF (VGK), which holds ~2% of its total assets in Roche Holdings.


More From Market Realist